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Summary We examined 159 consecutive cases of non-small-cell lung cancer (NSCLC) for a mutation at codon 12 of the K-ras gene and for
a mutation of the p53 gene occurring in exons 5-8. Eleven (6.9%) had mutations of the K-ras (ras+) and 57 (35.8%) had mutations of the p53
(p53+). There were 95 cases (59.7%) with ras -p53 -, seven cases (4.4%) with ras+/p53 -, 53 cases (33.3%) with ras-/p53+ and four cases
(2.5%) with ras+/p53+. The ras+ group had a worse prognosis than the ras - group in all cases and in 107 early-stage cases (stage l-ll,
P<0.05). The p53+ group had a worse prognosis in 107 early-stage cases (P<0.01), but there was no statistically significant difference when
52 advanced-stage cases (stage III-IV) or all patients were considered. Both ras and p53 mutations were unfavourable prognostic factors in
94 cases with adenocarcinoma, butthere was no statistical significance in 57 cases with squamous cell carcinoma. According to Cox's model,
the pathological stage, ras mutation and p53 mutation were found to be independent prognostic factors. Our results suggest that ras and p53
mutations were independent unfavourable prognostic markers especially in the early stage of NSCLC or in adenocarcinoma.
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Lung cancer has one of the most unfavourable prognoses among
the various human malignant tumours. We sometimes experience
early recurrence in early-stage patients and it is not rare for distant
metastases to occur after a complete resection of small cancers
measuring less than 2 cm in diameter. However, it is often difficult
to distinguish these unfavourable patients from others with abetter
prognosis based on the existing diagnostic tools.
Recent advances in molecular biology have now enabled us to
identify various oncogenes and tumour-suppressor genes that are
involved in carcinogenesis and the progression of cancer. In non-
small-cell lung cancer (NSCLC), mutations of the ras oncogene
and p53 tumour-suppressor gene are two of the most frequent
genetic alterations detected so far (Minna, 1993).
A ras gene mutation is detected in 10-30% of NSCLC cases,
and 80% of ras mutations occurred at codon 12 ofthe K-ras gene
(Rodenhuis et al, 1988; Bos et al, 1989; Slebos et al, 1990;
Mitsudomi et al, 1991a,b; Sugio et al, 1992). ras mutations are
more frequent in adenocarcinoma than in squamous cell carci-
noma but are absent in small-cell lung cancer (Rodenhuis et al,
1988; Mitsudomi et al, 199ib). Several investigators have reported
that ras mutations are a poor prognostic factor in NSCLC (Slebos
et al, 1990; Mitsudomi et al, 1991a). Our group also indicated that
ras mutations are a poor prognostic marker in node-negative
adenocarcinoma in human lung cancer (Sugio et al, 1992).
On the other hand, the p53 gene is one of the most frequently
mutated tumour-suppressor genes in human tumours. Thep53 gene
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regulates the cell cycle negatively through the transactivation ofthe
p21/Waf] gene and, in some cases, it induces apoptosis through the
transactivation oftheBaxgene (El-Deiry etal, 1993; Selvakumaran
et al, 1994). In NSCLC, p53 mutations are found in about half of
the tumours (Iggo et al, 1990; Levine et al, 1991; McLaren et al,
1992; Miller et al, 1992; Suzuki et al, 1992; Mitsudomi et al, 1992,
1993; Passlick et al, 1995), and it is more frequent in squamous cell
carcinoma than in adenocarcinoma (Iggo et al, 1990; McLaren et
al, 1992; Miller et al, 1992; Mitsudomi et al, 1993; Passlick et al,
1995). It is controversial, however, as to whether the presence of
p53 gene mutations in NSCLC has any prognostic value (McLaren
et al, 1992; Horio et al, 1993; Mitsudomi et al, 1993; Passlick et al,
1995; Lee et al, 1995).
It has been reported that the mutated ras gene requires an
immortalizing gene, such as either myc or a mutated p53 gene, to
transform primary rat embryo fibroblasts in vitro (Land et al,
1983; Eliyahu et al, 1984; Parada et al, 1984; Yancopoulos et al,
1985; Hunter, 1991). However, it has not been clarified as to
whether ras and p53 mutations combine to result in an
unfavourable prognosis for patients with NSCLC.
In this study, we simultaneously evaluated ras gene and p53
gene mutations and tried to correlate the findings with the prog-
noses of patients with NSCLC who had been surgically treated
consecutively in our department.
MATERIALS AND METHODS
Patients and tumour samples
From April 1990 to December 1993, 162 consecutive Japanese
patients with NSCLC underwent a pulmonary resection at the
Second Department of Surgery, Kyushu University Hospital.
Excluding four samples with poor preservation, 159 samples
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(one case had double primary lung cancer ofadenocarcinoma and
squamous cell carcinoma) were included in this study. They
included 103 men and 56 women, with ages ranging from 35 to 82
years (median 65 years). There were 94 patients with adenocarci-
noma, 57 with squamous cell carcinoma, four with large-cell
carcinoma and four with adenosquamous cell carcinoma.
According to the TNM classification system, 82 patients were
stage I, 25 were stage II, 26 were stage IIIA, 11 were stage IIIB
and 15 were stage IV. The median follow-up period was 624 days
(range 30-1660 days). These 159 tumour tissue samples (155
frozen materials and four formalin-fixed paraffin-embedded mate-
rials) were examined for mutations of the ras and p53 genes
[46 cases were also analysed for ras mutation in our previous
study (Sugio et al, 1992)].
DNA preparation
From the frozen samples and the formalin-fixed paraffin-
embedded samples, high molecular weight DNA was isolated as
described previously (Sugio et al, 1988). These high molecular
weight DNAs were stored in a TE buffer (10 mm Tris-HCI, 1 mM
EDTA, pH 8.0) at 4°C until the time ofexamination.
Detection of the point mutation at codon 12 of the K-ras
oncogene
Although ras mutations occureitherat codons 12, 13 and 61 ofthe
K-, H- and N-ras oncogene in various human cancers (Bos, 1989),
about 80% of all ras mutations are at codon 12 of the K-ras gene
in NSCLC (Rodenhuis et al, 1988; Bos et al, 1989; Slebos et al,
1990; Mitsudomi et al, 1991a,b; Sugio et al, 1992). In fact, in our
previous study (Sugio et al, 1992), 15 of 18 ras mutations (83%)
were present at this particular codon. Therefore, we concentrated
our effort on codon 12 of the K-ras gene to avoid any unneces-
sarily extensive screening. A polymerase chain reaction
(PCR)/designed restriction fragment length polymorphism
(RFLP) analysis using a mismatched primer was done to detect the
point mutations at codon 12 ofthe K-ras gene as described previ-
ously (Mitsudomi et al, 1991b). Our method was able to detect all
six possible mutations occurring at codon 12 of the K-ras gene
(Mitsudomi et al, 1991b). This method could also detect at least
10% ofmutant alleles in a background ofwild-type allele.
Detection of the point mutations of the p53 tumour-
suppressor gene
Four fragments ofDNA, each encompassing exons 5-8 ofthep53
gene, were amplified by the PCR technique. The nucleotide
sequences of the primers and the PCR conditions are available
upon request. The detection of point mutations of the p53 gene
was done by using a single-strand conformation polymorphism
(SSCP) technique (Orita et al, 1989). The PCR product was
diluted 1:8 with a loading buffer, and loaded on to four types of
gels containing either 8% or 12% polyacrylamide with or without
5% glycerol in order to raise the sensitivity for detecting a muta-
tion. The size ofthe gel was 14 x 13 cm. Electrophoresis was done
in an air-conditioned room at 10°C with a cooling fan for over 8 h
in order to detect mutated bands. The gel was subsequently silver
stained using a commercial kit (Silver Stain 'DAIICHI', Daiichi
Pure Chemicals, Tokyo, Japan).
Statistical analysis
The data were analysed by Student's t-test and the x2 test in a
unifactorial analysis of various clinical and pathological factors.
The survival curve was created by the Kaplan-Meier method
(Kaplan and Meier, 1958) and statistical significance was calcu-
lated by the log rank test (Peto et al, 1977). We calculated a 75%
survival time as the indicator for prognosis, because some of the
subgroups did notreach the median survival time during the obser-
vation period. Cox's multivariate regressions analysis (Kalbfleisch
and Prentice, 1980; Hopkins, 1990) was performed to select inde-
pendent factors affecting the overall survival. The difference was
considered to be significant when the two-sided P-value was less
than 0.05.
RESULTS
Frequency of ras mutation and p53 mutation
Of the 159 specimens examined, 11 samples (6.9%) had a muta-
tion ofthe K-ras gene at codon 12, while 57 samples (35.8%) had
a mutation ofthep53 gene. Twenty-one ofthep53 mutations were
in exon 5, five in exon 6, 17 in exon 7 and 17 in exon 8 (three
samples with double mutations in exon 6 and 7, 5 and 8, 7 and 8).
Ninety-five samples (59.7%) had neither ras nor p53 mutations
(ras-/p53-), seven (4.4%) had only ras mutations (ras+/p53-), 53
(33.3%) had only p53 mutations (ras -/pS3+) and four (2.5%) had
both ras and p53 mutations (ras-/p53+). The incidence of ras
mutations in thep53 mutation group (4/57, 7.0%) was not signifi-
cantly different from that in ap53 wild-type group (7/102, 6.9%),
which suggested that ras mutations and p53 mutations occurred
independently ofeach other (P=1.00).
Clinical and pathological status (Table 1)
There was a tendency for ras+ cases to be more frequent in adeno-
carcinoma (10%) than in squamous cell carcinoma (2%) (P=0.09).
On the otherhand,p53 mutations were more frequent in squamous
cell carcinoma (46%) than in adenocarcinoma (27%) (P=0.01).
p53 mutations were more prevalent in men (47%) than in women
(16%). The Brinkman Index (numberofcigarettes perday x years)
for pS3+ tumours (800) was higher than that for p53 - tumours
(360) (P<0.001). However, there was no association between ras
or p53 mutations and other clinical parameters, including patho-
logical stage and histological differentiation.
Univariate analysis for survival of the patients
Univariate analyses of various factors for overall survival are
shown in Table 2. Advanced pathological stage (stage III-IV)
(P<0.0001), poor histological differentiation (P=0.02) and a ras
mutation (P=0.04) were all found to be significant unfavourable
prognostic factors. Men tended to have a worse prognosis than
women (P=0.08). However,p53 mutations were not recognized as
a prognostic factor by a univariate analysis in all NSCLC patients,
but in 107 early-stage patients (stages I-II), p53 mutations were a
significantly unfavourable prognostic factor (P=0.01).
When we analysed the survival by stratifying the histological
types, we noticed an interesting trend. In patients with adenocarci-
noma, ras and p53 mutations were both unfavourable prognostic
factors. On the contrary, p53 gene mutations had no statistically
British Journal of Cancer (1997) 75(8), 1125-1130 . Cancer Research Campaign 1997Prognostic indicators in NSCLC 1127
Table 1 Association between K-ras gene mutations or p53 gene mutations and various clinical features
in patients with NSCLC
Clinical feature Number of patients ras mutation p53 mutation
(cases) (%) (%)
Total patients 159 6.9 35.8
Age (median 65 years)
570 years 103 6.8 34.0
70+ years 56 7.1 39.3
Sex
Male 103 7.8 46.6i
Female 56 5.3 16.1
Brinkman index (median 735)
5400 59 3.4 15.3
>400 96 9.4 47.9]
Histological type
Adenocarcinoma 94 9.6 26.6
Squamous cell carcinoma 57 1.8 4516
Large-cell carcinoma 4 25.0 75.0
Adenosquamous cell carcinoma 4 0.0 75.0
Histological differentiation
Well/moderately differentiated 116 4.3 35.3
Poorly differentiated 28 10.7 35.7
Unclassified 15 20.0 40.0
Pathological stage
l/ll 107 7.5 35.5
IIIA/IIIB/IV 52 5.8 36.5
ap<4.01; bp<Q.05.
Table 2 Univariate analysis of survival in patients with NSCLC
Factor 75% survival P
(months)
Age (years)
570 27
70+ 23 0.99
Sex
Male 17
Female 37 0.08
Brinkman's smoking index
!400 35
>400 18 0.19
Histological type
Adenocarcinoma 30
Squamous cell carcinoma 20 0.33
Histological differentiation
Well/moderately 30 0.02
Poorly 10 00
Pathological stage
l/li Not reached
IIIA/IIIB/IV 11 0.00
ras mutation
Negative 30
Positive 11 004
p53 mutation
Negative 30
Positive 18 0.15
significant impact on the survival of patients with squamous cell
carcinoma (Figure 1). Unfortunately, owingtothelow mutationrate,
noconclusions could be maderegarding the effect ofrasgene muta-
tions on the prognosis ofpatients with squamous cell carcinoma.
When both ras andp53 mutations were considered, as expected,
the ras -IpS3 - group had the longest survival, while the ras+lp53 -
and ras+lp53+ group had a similarly poor prognosis and the
ras -/p53+ group had an intermediate prognosis (Figure 2A). The
difference between the ras -/p53 -group and the otherthree groups
was statistically significant. When this analysis was done with a
stratification ofdisease stage, the effects of ras andp53 mutations
weregreaterin asubsetof 107patients withearly disease(Figure2B)
than in those with advanced disease (Figure 2C).
Cox's multivariate regression analysis (Table 3)
To see which independent factors had ajointly significant effect on
overall survival, we performed Cox's multivariate regression
analysis. The potential prognostic variables initially included were
age (70 years or under vs over 70 years), sex (men vs women), the
Brinkman index (400 or under vs over 400), the pathological stage
(stages I and II vs III and IV), histological type (adenocarcinoma vs
squamous cell carcinoma), histological differentiation (well or
moderately differentiated vs poorly differentiated), ras mutation
(ras+ vs ras-) and p53 mutation (pS3+ vs pS3 -). After a stepwise
selection of the variables, pathological stage, ras mutation andp53
mutation were allrecognized as independentprognostic factors. The
relative risk ofdeath for the ras+ patients and thepS3+ patients was
5.6 and 2.2 respectively. Therefore, the relative risk of death for
patients with ras+/pS3+ tumours was calculated tobe 12.3 (2.2 x 5.6)
compared with that ofpatients with neitherofthe two mutations.
DISCUSSION
We examined 159 NSCLC patients for both K-ras mutations
occurring at codon 12 and p53 mutations occurring in exons 5-8.
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Figure 1 The Kaplan-Meier survival curve with respect to the ras gene and p53 gene mutation. (A) In patients with adenocarcinoma. (B) In patients with
squamous cell carcinoma
Mutations at codon 12 of the K-ras gene were found in 6.9% of
NSCLC tumours, with a tendency for ras+ cases to be more frequent
in adenocarcinoma than in squamous cell carcinoma, as has been
reported previously (Rodenhuis et al, 1988). This incidence is a little
low compared with that reported previously (Rodenhuis et al, 1988;
Sugio et al, 1992). We also noted that the incidence of K-ras muta-
tions in tumours resected before 1990 was somewhat higher (13.0%,
15/115). The incidence appeared to decline with time. In tumours
resected from 1990 to 1991 the incidence was 11.3% (8/71) and in
tumours from 1992 or laterit was 3.4% (3/88) in this study. We have
noexplanation forthis change, butthe low incidence is notcausedby
low sensitivity of our assay. We could confirm all K-ras mutations at
codon 12 that had been detected by the dot-blotting method using
allele-specific probes in our previous study. This change in the inci-
dence of ras mutations may thus reflect a change in the lung cancer
aetiology in Japan. Although adenocarcinoma of the lung has been
on the increase in Japan, this increase may result from adenocarci-
nomas that are not associated with K-ras gene mutations. Previous
studies, including ours, showed that ras mutations are one of the
unfavourable prognostic factors (Slebos et al, 1990; Mitsudomi et al,
1991a; Sugio et al, 1992). By subsequently adding 113 patients, we
were able to confirm the prognostic impact of ras gene mutation.
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Figure 2 The Kaplan-Meier survival curve with respect to the ras gene and
p53 gene mutation. P-values were for all four groups using the log rank test.
(A) In all NSCLC patients. The ras -/p53 - group had a significantly better
prognosis than the ras -/p53+ group (P<0.05). (B) In early-stage patients
(stages and 11). Statistically significant differences were observed between the
ras -/p53 - group and the ras -/p53+ group (P<0.01), between the ras -/p53 -
group and the ras+/p53 - group (P<1).05), and between the ras -/p53 - group
and the ras+/p53+ group (P<0.05). (C) In advanced stage patients (stages
IlIl and IV)
A p53 mutation was detected in 35.8% of the cases with a
tendency for p53+ cases to be more frequent in squamous cell
carcinoma than in adenocarcinoma, thus confirming the previous
results (Iggo et al, 1992; Kishimoto et al, 1992; McLaren et al,
1992; Mitsudomi et al, 1993). We found that p53 mutation was a
significant prognostic factor in 107 cases with early-stage disease
(stages I and II) (P=0.01) but when all patients were considered,
p53 mutation was not found to be a prognostic marker (P=0.20).
However, Cox's multivariate regression analysis indicated thatp53
mutations were an independent, unfavourable prognostic factor.
The effect of these mutations might have been diluted in
advanced-stage patients, since advanced lung cancer is a heteroge-
neous group ofpatients, i.e. some patients have chest wall invasion
without lymph node involvement, while others have bulky metas-
tasis to the mediastinal lymph nodes. p53 mutations were an
unfavourable prognostic factor in patients with adenocarcinoma
but not at all in patients with squamous cell carcinoma, in spite of
its higher frequency. These findings are also in accordance with
Table 3 Significant prognostic factors selected by Cox's regression analysis
in patients with NSCLC
Factor P Relative risk of 95% confidence
death interval
ras mutation 0.00
Negative 1
Positive 5.6 2.1703-14.196
p53 mutation 0.03
Negative 1
Positive 2.2 1.1078-4.4407
Pathological stage 0.00
Stage I and 11 1
Stage IlIl and IV 4.5 2.1966-9.2044
The regression coefficients (bi) were converted to relative risks by computing
exp(bi). The 95% confidence interval for the relative risk was computed as
[exp(bi-1.96s.e.), exp(bi+1.96s.e.)], where s.e. was an estimated standard
error of bi.
previous reports including ours, dealing with a different set of
NSCLC patients (Mitsudomi et al, 1995; Nishio et al, 1996). This
fact may therefore suggest thatp53 mutations play a different role
in adenocarcinoma and in squamous cell carcinoma. The prog-
nostic impact of p53 gene mutation is still controversial. Some
studies have reported that p53+ cases had a worse prognosis
(Mitsudomi et al, 1993; Horio et al, 1993), while others reported
the opposite results (Passlick et al, 1995; Lee et al, 1995). One of
the reasons for such conflicting results may be owing to some
unintentional bias in the patient selection. To avoid such bias, we
tried to analyse consecutive patients as much as possible. In addi-
tion, some ofthe controversy regarding the results may be caused
by the use ofdifferent methodologies, i.e. a mutational analysis at
the DNA level vs an overexpression study using an immunohisto-
chemistry or different distribution of histological subtypes.
Furthermore, the effect of mutations on p53 function is not
uniform. Different p53 mutations (types and positions) have
different biological effects, such as transactivation (Raycroft et al,
1990) or binding to the heat shock protein (Hind et al, 1990), and
p53 mutations in the zinc-binding domains L2 (codons 163-195)
and L3 (codons 236-251) are also associated with a poor prog-
nosis in breast cancer (Borresen et al, 1995). These facts may also
account for some ofthe discrepancies among the different studies.
Our data suggested that ras and p53 mutations occur indepen-
dently and correlated with the findings of previous reports
(Mitsudomi et al, 1992; Kishimoto et al, 1992). Cox's multivariate
regression analysis revealed that ras mutation and p53 mutation
were independent prognostic markers together with pathological
stage (see Table 3). It is thus calculated that ras+/p53+ cases will
have a worse prognosis with a relative risk of death of 12.3
compared with ras -Ip53 - cases.
Itisbelieved thathuman canceroccurs anddevelops with an accu-
mulation ofmultiple genetic alterations (Weinberg, 1989; Fearon and
Vogelstein, 1990). Previous reports revealed that alterations ofmyc,
c-erbB-2, bcl-2, RB and MTSJ/p16 genes are involved in the patho-
genesis and development of NSCLC in addition to the ras andp53
genes (Minna, 1993). Furthermore, putative tumour-suppressor
genes at chromosomes 3p, 5q, 8p and lIp are also believed to play a
role in NSCLC (Minna, 1993). Although not all of these genetic
alterations may be prognostic indicators, our results suggested
that ras and p53 mutations are an independent poor prognostic
marker in NSCLC. Kern et al (1994) reported that the expression
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of ras and erbB-2 is an independent poor prognostic indicator in
lung adenocarcinoma, while Xu et al (1994) reported that the loss
of retinoblastoma susceptibility gene product expression and the
nuclear accumulation of the p53 protein independently contribute
to the adverse outcome in stage I and II lung cancer. Further
studies dealing with a larger number of patients (possibly in a
prospective fashion) are needed to elucidate the prognostic impact
ofvarious genetic alterations in NSCLC. It remains to be clarified,
however, whether or not the prognosis of NSCLC patients with
these poor genetic markers can be improved by either aggressive
or investigational therapeutic approaches.
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